Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07226791 | Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair | PHASE2 | RECRUITING | 200 | — | — | Feb 4, 2026 | May 1, 2030 | Jun 2, 2026 | 11 | United States |
PFC will be defined as the ability to achieve fascia to fascia midline approximation.
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| AGN-151607-DP Dose A | EXPERIMENTAL | Participants will receive AGN-151607-DP Dose A on Day 1. |
| AGN-151607-DP Dose B | EXPERIMENTAL | Participants will receive AGN-151607-DP Dose B on Day 1. |
| AGN-151607-DP Dose C | EXPERIMENTAL | Participants will receive AGN-151607-DP Dose C on Day 1. |
| Placebo for AGN-151607-DP | PLACEBO_COMPARATOR | Participants will receive Placebo for AGN-151607-DP on Day 1. |
| Name | Type | Description |
|---|---|---|
| AGN-151607-DP | DRUG | Intramuscular Injection |
| Placebo for AGN-151607-DP | DRUG | Intramuscular Injection |
Inclusion Criteria: \- Midline ventral hernia requiring open surgical repair. Exclusion Criteria: * Medical condition that may put the participant at increased risk with exposure to AGN-151607-DP, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eat...